BIOLASE INC's gross profit margin for the third quarter of its fiscal year 2014 has significantly increased when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. BIOLASE INC has weak liquidity. Currently, the Quick Ratio is 0.68 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 16.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY14||Q3 FY13|
|Net Sales ($mil)||12.71||12.35|
|Net Income ($mil)||-3.5||-4.05|
|Balance Sheet||Q3 FY14||Q3 FY13|
|Cash & Equiv. ($mil)||2.76||4.15|
|Total Assets ($mil)||29.9||32.86|
|Total Debt ($mil)||0.0||5.53|
|Profitability||Q3 FY14||Q3 FY13|
|Gross Profit Margin||43.21||31.44|
|Return on Assets||-57.03||-24.97|
|Return on Equity||-153.66||-86.38|
|Debt||Q3 FY14||Q3 FY13|
|Share Data||Q3 FY14||Q3 FY13|
|Shares outstanding (mil)||43.95||35.2|
|Div / share||0.0||0.0|
|Book value / share||0.25||0.27|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||143342.0||310432.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 10.61 indicates a significant premium versus the S&P 500 average of 2.76 and a significant premium versus the industry average of 4.93. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a premium to investment alternatives within the industry.
|BIOL NM||Peers 39.49||BIOL NM||Peers 40.18|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BIOL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BIOL's P/CF is negative making the measure meaningless.
|BIOL NM||Peers 28.41||BIOL NA||Peers 1.03|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BIOL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BIOL 10.61||Peers 4.93||BIOL -71.35||Peers 19.56|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BIOL is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BIOL is expected to significantly trail its peers on the basis of its earnings growth rate.
|BIOL 2.37||Peers 5.71||BIOL -17.61||Peers 7.34|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BIOL is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BIOL significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV